Russia Says One-Shot Sputnik Light Vaccine Has 79% Efficacy
(Bloomberg) -- Russia has approved a single-dose version of the Sputnik V Covid-19 vaccine after it showed almost 80% efficacy, according to the state-run fund that backed its development.
The 79.4% efficacy rate of the vaccine, called Sputnik Light, is based on an analysis of real-world data rather than a standard clinical trial, and interim results from final-stage study are expected later this month, according to a statement Thursday from the Russian Direct Investment Fund. Early and mid-stage studies showed no serious adverse events, RDIF said.
One injection of Sputnik Light “significantly reduces the possibility of severe cases leading to hospitalization,” RDIF said in the statement.
Russia's two-dose Sputnik V vaccine rivaled other major shots used in the U.S. and Europe when it showed 92% effectiveness against Covid-19 in a peer-reviewed study. There had been initial skepticism when President Vladimir Putin announced last August that Russia had cleared the world's first Covid-19 vaccine for use before it even completed safety trials.
While RDIF said more than 20 million people globally have now received one dose of Sputnik V, Russia is having trouble persuading its own citizens to get vaccinated. Only about 8% of the population has had the first dose amid fears of a rising wave of infections.
The two-dose Sputnik V will remain the main vaccine in Russia, Kirill Dmitriev, RDIF chief executive officer, said in a telephone interview. The light version “is mostly for countries that have a significant Covid surge that they need to put down quickly,” he said.
“We expect registration of Sputnik Light in several countries as early as next week,” Dmitriev said, adding that the fund was following Russian regulatory procedures.
Since the vaccine is the same as the first dose of Sputnik V, “we believe that by June Sputnik Light will be registered pretty much in most of the countries that registered Sputnik V,” Dmitriev said in a webinar. Sputnik Light may also work as “a booster shot” to other Covid-19 vaccines in protecting against mutations of the virus, subject to additional clinical trials, he said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.